RecruitingNCT06417710

Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis

Sponsor

University of Zurich

Enrollment

200 participants

Start Date

Jan 30, 2022

Study Type

OBSERVATIONAL

Conditions

Leptomeningeal Disease Leptomeningeal Metastasis Leptomeningeal Neoplasms Leptomeningeal Cancer

Summary

The goal of this project is to develop and validate a reproducible scorecard for the neurological assessment of patients with leptomeningeal metastases that can be used in clinical trials including such patients, as well as in clinical practice.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Neurological Assessment for people with leptomeningeal cancer, leptomeningeal disease, and other related conditions. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNeurological Assessment

Clinical neurological assessment performed by 2 raters

Locations(3)

MD Anderson Cancer Center

Houston, Texas, United States

Netherlands Cancer Institute

Amsterdam, Netherlands

University Hospital Zurich

Zurich, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06417710

Related Trials

Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD

NCT076949861 location

Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

NCT024226413 locations

Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease

NCT074150181 location

Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer

NCT064316851 location

Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study

NCT073985991 location